Desquamative interstitial pneumonia

disease
On this page

Also known as DIPinterstitial pneumonitis, desquamative, familialRBILDrespiratory bronchiolitis interstitial lung disease

Summary

Desquamative interstitial pneumonia (MONDO:0009887) is a disease and 2 clinical trials. Top therapeutic interventions include bardoxolone methyl. A subtype of idiopathic interstitial pneumonia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namedesquamative interstitial pneumonia
Mondo IDMONDO:0009887
MeSHC562470
OMIM263000
Orphanet98852
DOIDDOID:0050158
ICD-10-CMJ84.117
ICD-111620001155
NCITC35288
SNOMED CT8549006
UMLSC0238378
MedGen65962
GARD0016864
Is cancer (heuristic)no

Also known as: desquamative interstitial pneumonia · DIP · interstitial pneumonitis, desquamative, familial · RBILD · respiratory bronchiolitis interstitial lung disease

Disease family

This is a subtype of idiopathic interstitial pneumonia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorderrespiratory tract infectious disorderpneumoniaidiopathic interstitial pneumoniadesquamative interstitial pneumonia

Related subtypes (9): lymphoid interstitial pneumonia, cryptogenic organizing pneumonia, combined pulmonary fibrosis-emphysema syndrome, acute interstitial pneumonia, respiratory bronchiolitis-interstitial lung disease syndrome, non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, follicular bronchiolits, idiopathic pulmonary fibrosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE21
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02036970PHASE2COMPLETEDBardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
NCT02019641Not specifiedCOMPLETEDThe NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BARDOXOLONE METHYL31
CHEMBL446036001
CHEMBL520574101